James Miller

Dr. James Miller

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Journal of Mammary Gland Biology and Neoplasia
Verified
Journal Article
Closed access
PDF file
JMJames Miller
James Miller
ABArianna P. Bartlett
Arianna P. Bartlett
RHRebecca M. Harman
Rebecca M. Harman
PMPrabin Dhangada Majhi
Prabin Dhangada Majhi
DJD. Joseph Jerry
D. Joseph Jerry
GWGerlinde Van de Walle
Gerlinde Van de Walle

3 October 2022 in Journal of Mammary Gland Biology and Neoplasia
Verified
Journal Article
Closed access
PDF file
JMJames Miller
James Miller
MKMatt Kanke
Matt Kanke
GRGat Rauner
Gat Rauner
KBKimaya Bakhle
Kimaya Bakhle
PSPraveen Sethupathy
Praveen Sethupathy
GWGerlinde Van de Walle
Gerlinde Van de Walle

20 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AKAdam McLain Kase
Adam McLain Kase
WTWinston Tan
Winston Tan
JGJustyna Gleba
Justyna Gleba
JMJames Miller
James Miller
NMNathalie Meurice
Nathalie Meurice
JCJohn A. Copland
John A. Copland
176 Background: Despite androgen deprivation therapy, prostate cancer will develop resistance known as castrate resistant prostate cancer (CRPC). Androgen signaling is associated with pathways that influence cell proliferation and survival via cell cycle regulation. AR signaling results in inactivation of Rb tumor suppressor by way of AKT and reduction in intrinsic CDK4/6 inhibitors. Since PTEN loss is found in 40% of mCRPC and AKT pathway is a mechanism of CDK4/6 inhibitor resistance, we hypothesize adding an AKT inhibitor to a CDK4/6 inhibitor will have synergistic activity while delaying CDK4/6 inhibitor resistance. Preclinical xenografts have been shown to recapitulate patient response, therefore, can be used to guide clinical trials using novel combinations. Methods: We have established patient derived tumor xenograft models (GUR-017M, TMA-027 and PRJ-88T) from patients with mCRPC with each having a unique genomic alteration profile. In the clinical setting, GUR-017M was resistant to abiraterone, enzalutamide, cabazitaxel and had exposure to docetaxel. TMA-027 and PRJ-88T were resistant to enzalutamide. We combined a CDK4/6 inhibitor with an AKT inhibitor and treated each of these patient tumors in NOD-SCID mice for a total duration of 40 days. Mice were implanted and separated into 4 groups (placebo, CDK4/6 inhibitor, AKT inhibitor and CDK4/6 + AKT inhibitor) with 10-13 mice in each group. Tumor volumes were measured twice a week. For GUR-017M, abemaciclib (50 mg/kg) was combined with MK2206 (120 mg/kg) and was compared to each placebo and each single agent alone. For TMA-027, palbociclib (50 mg/kg) was combined with ipatasertib (50 mg/kg). After 40 days, tumors were harvested for immunohistochemistry analysis. PRJ-88T was grown as 3D spheroids in ultra-low attachment plates and treated with palbociclib + ipatasertib (10 uM-100uM) to evaluate for synergy. Results: GUR-017M and TMA-027 showed significant delayed tumor growth compared to placebo or either single agent alone. In the GUR-017M group, the final mean tumor volume for the combination group was 149 mm3, compared to 377 mm3 (abemaciclib), 358 mm3 (MK2206) and 527 mm3 placebo group, representing a percent decrease compared to control by 72%, 29%, and 32%, respectively. For TMA-027, the final mean tumor volume for the combination group was 102 mm3, compared to 259 mm3 (palbociclib), 416 mm3 (ipatasertib), and 402 mm3 placebo group, representing a percent decrease compared to control by 75%, 36%, and 4%, respectively. PRJ-88T 3D spheroids showed synergy with palbociclib + ipatasertib. In vivo experiments using PRJ-88T are in progress. Conclusions: The preclinical results show combining CDK4/6 inhibitors with AKT inhibitors is a promising treatment strategy and provides the basis for a clinical trial in patients with mCRPC.

Verified
Journal Article
Open access
PDF file
JMJames Miller
James Miller
MDMariza DaCosta
Mariza DaCosta
KBKimaya Bakhle
Kimaya Bakhle
LLLisa Lai
Lisa Lai
DPDawn E. Post
Dawn E. Post
GWGerlinde Van de Walle
Gerlinde Van de Walle
Accurate assessment of early indicators of breast cancer (BC) is critical to improve detection strategies and patient prognosis. Our research group takes a comparative species approach to study early BC detection by capitalizing on data from species with inherently low or high incidence of mammary cancer to supplement rare human samples. Circulating microRNAs (c-miRNAs) are a promising class of molecules that have the potential to serve as biomarkers for BC risk and disease detection. The expression of these non-coding RNAs controls numerous cellular processes and their dysregulation is associated with various pathological conditions, including cancer. To explore whether c-miRNA expression profiles can identify individuals with early-stage BC, we conducted a multi-species pilot study. We analyzed biofluid samples (i.e., saliva, serum, and plasma) from patients with early-stage BC and patients with no prior history of cancer and mammosphere-derived epithelial cells (MDECs) from dogs (canines) and horses (equines), species with a relatively high and low incidence of mammary cancer, respectively. We identified 16 candidate c-miRNAs that were upregulated in saliva from patients in the early-stage BC group when compared to the control patient group. Notably, 6 of these c-miRNAs (i.e., miR-361, miR-148b, miR-205, miR-186, miR-223, and miR-197) were also found to be secreted at higher levels by canine MDECs when compared to equine MDECs. Although individual and combinatorial assessment of these six c-miRNAs in a larger human cohort did not confirm their potential association with early breast cancer detection, the data in this study do introduce a novel comparative framework in which species-to-species variation in cancer susceptibility may inform the identification of candidate biomarkers for human disease.